Investments
137Portfolio Exits
58Funds
18Partners & Customers
1Service Providers
2About Ampersand Capital Partners
Ampersand Capital Partners is a middle market private equity firm focused on investments in the Healthcare and Industrial sectors. It prefers to be the first, and usually sole, institutional investor.
Ampersand Capital Partners Headquarters Location
55 William St Suite 240
Wellesley, Massachusetts, 02481,
United States
Expert Collections containing Ampersand Capital Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Ampersand Capital Partners in 2 Expert Collections, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
237 items
Synthetic Biology
382 items
Latest Ampersand Capital Partners News
Aug 5, 2022
Sterling's capabilities include the development of entire systems, including the incorporation of software, electronics, and mechanical components. Michael Barbella, Managing Editor08.05.22 Ampersand Capital Partners is investing in Sterling Medical Devices , a provider of design, development and regulatory services to the medical device industry. Details of the investment were not immediately available. “My team and I are humbled to join the Ampersand family. The Ampersand team’s extensive experience and network in the medical device industry positions Sterling to continue its strong growth trajectory and build on the world-class services we provide to our customers” said Dan Sterling, president and CEO of Sterling. Having successfully completed more than 1,500 projects for hundreds of unique customers, Sterling has commercialization experience across the entire medical device development process. Capabilities include the development of entire systems, including the incorporation of software, electronics, and mechanical components. These services are provided by U.S.-based personnel in an ISO-13485 environment, and all supported by the company’s Regulatory Affairs and Quality Assurance capabilities. “We are thrilled to be partnering with Dan and the entire Sterling team. With over two decades of experience bringing the most complex medical devices to market, the Sterling team has built a strong, solutions-oriented reputation with the medical device industry’s leading innovators," said Trevor Wahlbrink, a partner at Ampersand. "We look forward to building upon the company’s strong momentum by continuing to add capabilities to its already robust offering.” Located in Moonachie, N.J., Sterling Medical Devices provides custom electromechanical and software solutions for the medical device industry. For more than 21 years, the company’s experience in product development has helped healthcare companies bring their medical device software and hardware, electromechanical equipment, and mobile medical device apps to market. Sterling addresses the entire development process including systems, software, electronics, mechanical, quality, compliance, and regulatory affairs. Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Trending
Ampersand Capital Partners Investments
137 Investments
Ampersand Capital Partners has made 137 investments. Their latest investment was in Sterling Medical Devices as part of their Private Equity on June 6, 2022.
Ampersand Capital Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/23/2022 | Private Equity | Sterling Medical Devices | Yes | 1 | ||
6/7/2022 | Series C - II | AnaBios | $6.5M | Yes | 2 | |
5/25/2022 | Series A | Vernal Biosciences | $21M | Yes | 2 | |
3/29/2022 | Private Equity | |||||
3/1/2022 | Private Equity |
Date | 6/23/2022 | 6/7/2022 | 5/25/2022 | 3/29/2022 | 3/1/2022 |
---|---|---|---|---|---|
Round | Private Equity | Series C - II | Series A | Private Equity | Private Equity |
Company | Sterling Medical Devices | AnaBios | Vernal Biosciences | ||
Amount | $6.5M | $21M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 2 | 2 |
Ampersand Capital Partners Portfolio Exits
58 Portfolio Exits
Ampersand Capital Partners has 58 portfolio exits. Their latest portfolio exit was GenDx on August 17, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
8/17/2022 | Acquired | 2 | |||
2/18/2022 | Acquired | 3 | |||
2/18/2022 | Acquired | 2 | |||
Date | 8/17/2022 | 2/18/2022 | 2/18/2022 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 2 | 3 | 2 |
Ampersand Capital Partners Acquisitions
24 Acquisitions
Ampersand Capital Partners acquired 24 companies. Their latest acquisition was Protagen Protein Services on July 01, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
7/1/2021 | Acq - Fin | 1 | ||||
9/21/2020 | Acq - Fin | 1 | ||||
5/29/2019 | Acq - Fin | 4 | ||||
9/4/2018 | ||||||
1/31/2017 |
Date | 7/1/2021 | 9/21/2020 | 5/29/2019 | 9/4/2018 | 1/31/2017 |
---|---|---|---|---|---|
Investment Stage | |||||
Companies | |||||
Valuation | |||||
Total Funding | |||||
Note | Acq - Fin | Acq - Fin | Acq - Fin | ||
Sources | 1 | 1 | 4 |
Ampersand Capital Partners Fund History
18 Fund Histories
Ampersand Capital Partners has 18 funds, including Ampersand Continuation Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
11/19/2020 | Ampersand Continuation Fund | $670M | 2 | ||
3/31/2020 | Ampersand 2020 | Multi-Stage Venture Capital | Open | $690M | 3 |
3/19/2018 | Ampersand Capital Partners Fund I | Multi-Stage Venture Capital | Closed | $450M | 1 |
5/29/2015 | Ampersand 2014 LP | ||||
1/31/2011 | Ampersand 2011 LP |
Closing Date | 11/19/2020 | 3/31/2020 | 3/19/2018 | 5/29/2015 | 1/31/2011 |
---|---|---|---|---|---|
Fund | Ampersand Continuation Fund | Ampersand 2020 | Ampersand Capital Partners Fund I | Ampersand 2014 LP | Ampersand 2011 LP |
Fund Type | Multi-Stage Venture Capital | Multi-Stage Venture Capital | |||
Status | Open | Closed | |||
Amount | $670M | $690M | $450M | ||
Sources | 2 | 3 | 1 |
Ampersand Capital Partners Partners & Customers
1 Partners and customers
Ampersand Capital Partners has 1 strategic partners and customers. Ampersand Capital Partners recently partnered with GenDx on May 5, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
5/6/2019 | Partner | Netherlands | The partnership between Ampersand Capital Partners and GenDx aims to foster sustainable growth , both organically and through M&A activities in the molecular diagnostic products and services market . | 5 |
Date | 5/6/2019 |
---|---|
Type | Partner |
Business Partner | |
Country | Netherlands |
News Snippet | The partnership between Ampersand Capital Partners and GenDx aims to foster sustainable growth , both organically and through M&A activities in the molecular diagnostic products and services market . |
Sources | 5 |
Ampersand Capital Partners Service Providers
2 Service Providers
Ampersand Capital Partners has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Counsel | |||
Service Provider | ||
---|---|---|
Associated Rounds | ||
Provider Type | Counsel | |
Service Type |
Partnership data by VentureSource
Ampersand Capital Partners Team
8 Team Members
Ampersand Capital Partners has 8 team members, including current Chief Financial Officer, Dana Niles.
Name | Work History | Title | Status |
---|---|---|---|
Richard A. Charpie | Founder | Current | |
Dana Niles | YankeeTek Ventures, and HLM Venture Partners | Chief Financial Officer | Current |
Herbert H. Hooper | Managing Partner | Current | |
David Q. Anderson | General Partner | Current | |
Eric B. Lev | Water Street Healthcare Partners, Beckman Coulter, One Equity Partners, and Lehman Brothers | General Partner | Current |
Name | Richard A. Charpie | Dana Niles | Herbert H. Hooper | David Q. Anderson | Eric B. Lev |
---|---|---|---|---|---|
Work History | YankeeTek Ventures, and HLM Venture Partners | Water Street Healthcare Partners, Beckman Coulter, One Equity Partners, and Lehman Brothers | |||
Title | Founder | Chief Financial Officer | Managing Partner | General Partner | General Partner |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.